Please select


For My Business

< R10m annual turnover

For My Business

> R10m annual turnover

Please select


For My Business

< R10m annual turnover

For My Business

> R10m annual turnover

Switch to FNB Business

Product shop

By Turnover

First Business Zero (R0 - R5 million p.a) Gold Business (R0 - R5 million p.a) Platinum Business (R5 million - R60 million p.a) Enterprise Business (R60 million - R150 million+ p.a)

Transact

Business Accounts Credit Cards Cash Solutions Merchant Services eWallet Pro Staffing Solutions ATM Solutions Ways to bank Fleet Services Guarantees

Savings and Investments

Save and Invest 3PIM (3rd Party Investment Manager)

Borrow

FNB Cash Advance Overdraft Loans Debtor Finance Leveraged Finance Private Equity Securities Based Lending Selective Invoice Discounting Asset Based Finance Alternative Energy Solutions Commercial Property Finance Fleet Services

Insure

Insurance

For my employees

Staffing Solutions Employee benefits

Forex + Trade

Foreign Exchange Imports and exports Structured Trade + Commodity Finance Business Global Account (CFC account)

Value Adds + Rewards

Connect my business the dti initiatives Enterprise and supplier development Business Hub eBucks Rewards for Business DocTrail™ CIPC Integration Channel Instant Accounting Solutions Instant Payroll Instant Cashflow Instant Invoicing SLOW 24/7 Business Desk FNB Business Fundaba nav» Marketplace Prepaid products Accounting integrations

Industry Expertise

Philanthropy Chinese Business Islamic Banking Agriculture Public Sector Education Healthcare Franchise Motor Dealership Tourism

Going Global

Global Commercial Banking

Financial Planning

Overview

Bank Better

KYC / FICA Debit order + recipient switching Electronic Alerts

Corporates + Public Sector

Corporate Public Sector

All savings + investment accounts


Cash deposits

Notice deposits Immediate access Access to a portion Fixed deposits

Share investing

Shares

Tax-free investing

Tax-free accounts

Funds/unit trusts

Ashburton specialised products

Invest abroad

Offshore products

I want to save for

Personal goals Child's education Emergencies Tax-free

Compare similar

Compare

Additional options

Show me all Help me chosse Find an advisor

Financial planning

Overview

Back

Trade Ideas

Local Trade Idea: Clicks Group (CLS) - BUY

 

By Peet Serfontein & Zimele Mbanjwa

We initiate a long position with a target price of R399. We recommend a stop-loss at R331.

Clicks Group is a health and beauty-focused retail and supply group. Through its market-leading retail brands, Clicks, Sorbet, Claires and The Body Shop, the group has hundreds of stores across southern Africa, while United Pharmaceutical Distributors (UPD) provides distribution capability for the group's healthcare strategy and has close to a third of market share in private pharmaceutical wholesale in South Africa.

With a strategic focus on expanding its footprint and growing its private label offering, Clicks has maintained a resilient performance amid economic headwinds, supported by strong cash generation and defensive demand for healthcare services. Further to this, Clicks is characterised by its strong growth, high return on equity (ROE), strong cash conversion and execution.

Technically, the price is in a steep downward trend, which makes the share an interesting candidate for a long position (see the insert on the main chart).

When prices fall too quickly, the stock tends to become oversold relative to its fundamental value or historical norms, often triggering technical buying or short covering. Additionally, steep declines frequently exhaust sellers, creating conditions for a reversal as bargain hunters step in. If such a move is followed by a stabilisation in price or a bullish candlestick formation, it may indicate that the worst of the selling pressure has passed—thus laying the groundwork for a recovery or a bounce from oversold levels.

The price has rebounded from the 50% Fibonacci retracement level, which also supports a bullish bias.

Fading downside price momentum, according to the Moving Average Convergence Divergence (MACD) histogram and the downward trajectory according to the on-balance volume (OBV) indicator, supports the bullish undertone for the share.

The price remains below its 200-day simple moving average (SMA) of R364, which may signal a period of consolidation or base-building, suggesting that selling pressure is easing and buyers are beginning to accumulate.

We suggest a medium capital at-risk allocation to this trade. Increase exposure for a break above R360.

Share Information
Share Code CLS
Industry Food and Drug Retailers
Market Capital (ZAR) 91.84 billion
One Year Total Return 37.97%
Return Year-to-Date 21.15%
Current Price (ZAR) 385.77
52 Week High (ZAR) 403.39
52 Week Low (ZAR) 275.50
Financial Year End August
Despite recent weakness, the share has made solid progress year-to-date, with several technical indicators pointing to further upside potential.

Consensus Expectations
(Bloomberg)
FY24 FY25E FY26E FY27E
Headline Earnings per Share (ZAR) 11.94 13.54 15.47 17.49
Growth (%) 13.46 14.24 13.07
Dividend Per Share (ZAR) 7.76 8.70 9.93 11.23
Growth (%) 12.10 14.20 13.08
Forward PE (times) 26.61 23.29 20.60
Forward Dividend Yield (%) 2.41 2.76 3.12
Earnings growth is expected to remain robust over the forecast term.

Buy/Sell Rationale:

Technical Analysis:

    • The second chart highlights instances when the Relative Strength Index (RSI) entered oversold territory - indicated by a reading of one. An oversold RSI indicator can support a bull case by signalling that recent selling pressure may have been excessive and that the share could be due for a rebound.
    • This often attracts buyers who view the low RSI reading as a buying opportunity, especially if it aligns with other technical factors such as support levels or bullish price patterns.
    • Our entry range is between R340 and R360. A move away from this range will signify a change in trend and would negate this trade idea.
    • Our target price is R399, representing upside of ~12% from current levels.
    • Our proposed time to exit is towards end-June 2025, though investors can adjust for either a longer or shorter time horizon, depending on price behaviour.
    • A drop below R331 (downside of ~7.1% from current levels) would imply weakening technicals. As such, a stop-loss is recommended at this level.
    • Expect moderate volatility in the price.

Long term Fundamental view

    • Clicks has proven to be an excellent competitor in the retail and distribution space. The company is led by a strong management team who has improved various operational efficiencies, lowered costs, reduced excess investment in working capital and enhanced product availability. In addition, the company boasts a high return of equity, has minimal debt and is highly cash generative.
    • The group recently delivered a softer-than-expected 20-week trading update performance (to mid-January), with several notable metrics decelerating from the FY24 mark and turnover that was tracking behind full-year expectations. While Black Friday sales were good and supportive of market share gains across all product categories, the group's non-promotional sales exhibited slower growth while Christmas-related offerings failed to impress.
    • Nevertheless, we would expect an improvement in growth for the remainder of the financial year as store role outs accelerate. Momentum in UPD has been positive and is anticipated to further support the top line while having a less dilutionary impact as margins continue to improve following recent systems changes.
    • Furthermore, following the resolution of the Unicorn Pharmaceuticals licensing matter in August 2024, pharmacy licences are again being issued by the Department of Health, with Clicks being granted 27 new licences during the period. Clicks opened 11 new pharmacies in November and December and plans to accelerate the expansion programme in the months ahead.
    • Key risks to our fundamental view include regulatory intervention within the pharmaceutical sector, increased competition from food retailers introducing pharmacy offerings, as well as tariffs that pose supply chain and global growth risks that may slowdown discretional spending.

Share Name and Position VOD - BUY
(Take profit)
SHP - Stop Loss
(Close the position)
CML - Stop Loss
(Close the position)
Entry 109.87 292.78 37.75
Current 129.0 252.97 36.00
Movement +17.4% -13.6% -4.6%
The share reached our target price, so we took profit and closed the position. The trade breached our stop loss level, and we've exited the trade. The trade breached our stop loss level, and we've exited the trade

Share Name and Position TFG - Stop Loss
(Close the position)
APN - Stop Loss
(Close the position)
JSE - Stop Loss
(Close the position)
Entry 127.93 171.38 130.10
Current 116.87 160.93 123.89
Movement -8.6% -6.1% -4.8%
The trade breached our stop loss level, and we've exited the trade. The trade breached our stop loss level, and we've exited the trade. The trade breached our stop loss level, and we've exited the trade.

FNB Stockbroking and Portfolio Management (Pty) Ltd, a subsidiary of FirstRand Bank Limited, an authorised Financial Services Provider and authorised user of the JSE limited (Reg no: 1996/011732/07). This Publication note is issued by FNB Stockbroking and Portfolio Management (Pty) Ltd for the information of clients only and should not be produced in whole or part without prior permission. Although FNB Stockbroking and Portfolio Management (Pty) Ltd is an Authorised Financial Services Provider, any opinions and/or analysis contained in this Publication are for informational purposes only and should not be considered advice, including but not limited to financial, legal or tax advice, or a recommendation to invest in any security or to adopt any investment strategy. The information contained herein has been obtained from sources/persons which we believe to be reliable but is not guaranteed for correctness, completeness or otherwise and we do not assume liability for loss arising from errors in the information or that may be suffered from using or relying on the information contained herein irrespective of whether there has been any negligence by us, our affiliates or any other employees of us, and whether such losses be direct or consequential. As market and economic conditions are subject to rapid change, any comments, opinions, and analysis is rendered as of the date of publishing and may change without notice. Such changes may have a material impact on the outcome of any investment. Securities involve a degree of risk and are volatile instruments. Past performance is not indicative of future performances. Securities or financial instruments mentioned in the Publication note may not be suitable for all investors and FNB Stockbroking and Portfolio Management (Pty) Ltd has bares no responsibility whatsoever arising from or as a consequence hereof. The material is not intended as a complete analysis of every material fact regarding any share, instrument, sector, region, market, country, investment, or strategy. The recipient of this Publication must make their own investment decision and is advised to contact his relationship manager for a personal financial analysis prior to making any investment decisions. Copyright 2018 by FNB Stockbroking and Portfolio Management (Pty) Ltd.